The largest quarterly supply agreement in company history reflects strong market performance and expanding product portfolio.
슬롯 사이트, represented by its CEO Woo-sung Ki, revealed a monumental supply contract valued at 3 million on September 25th. The agreement encompasses a range of key products, including 'Remsima,' 'Remsima SC,' 'Yuflyma,' 'Truxima,' 'Herzuma,' and 'Vegzelma.'
This historic contract marks the most substantial quarterly supply deal in the company's annals. The surge in demand for antibody biosimilars across the United States and Europe, coupled with the success of newer offerings like Yuflyma and Vegzelma, has been identified as the driving force behind this remarkable growth. Furthermore, 슬롯 사이트 anticipates further revenue escalations in the second half of the year, driven by the addition of Teva's migraine treatment drug raw materials (CMO) supply volume by year-end.
According to IQVIA, a prominent pharmaceutical market research organization, 슬롯 사이트's product portfolio held notable market shares in the European market during the first quarter of this year. Remsima commanded a substantial 61.7% share, while Truxima and Herzuma maintained solid footholds at 22.1% and 19.2%, respectively. Notably, both Remsima and Truxima have surpassed the original products, leading the market.
In the U.S. market, as of the second quarter of this year, Remsima (branded as Inflectra) secured an impressive 30.2% market share, with Truxima closely trailing at 30.5%. 슬롯 사이트's strategic move to gain approval for Remsima SC (branded as Jim Pentra) in the United States is poised to bolster Remsima's market share, benefiting Jim Pentra's introduction to the U.S. market.
Within the major five European countries (EU5), Remsima SC achieved a substantial 17% market share in the first quarter of this year, with an impressive 33% share in Germany and a commendable 21% share in France. Collectively, Remsima and Remsima SC accounted for an impressive 68.5% market share within the EU5, according to the company's reports.
A 슬롯 사이트 representative expressed, "With the expansion of approvals and orders for next-generation products like Remsima SC and Yuflyma, alongside the increasing supply of existing biosimilar products such as Remsima and Herzuma, we are committed to maintaining a stable supply chain. As growth continues throughout the second half of this year and into the next, along with the launches of key products in various regions, we will strive to meet the rising demand in the market."